{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T06:26:29Z","timestamp":1764570389051},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,5,8]],"date-time":"2009-05-08T00:00:00Z","timestamp":1241740800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1007\/s00520-009-0645-z","type":"journal-article","created":{"date-parts":[[2009,5,7]],"date-time":"2009-05-07T10:55:59Z","timestamp":1241693759000},"page":"197-203","source":"Crossref","is-referenced-by-count":23,"title":["Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting"],"prefix":"10.1007","volume":"18","author":[{"given":"Mateya","family":"Trinkaus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Myers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Dranatisaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,5,8]]},"reference":[{"key":"645_CR1","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/sj.bjc.6604382","volume":"98","author":"RE Coleman","year":"2008","unstructured":"Coleman RE (2008) Risks and benefits of bisphosphonates. Br J Cancer 98:1736\u20131740. doi: 10.1038\/sj.bjc.6604382","journal-title":"Br J Cancer"},{"issue":"1","key":"645_CR2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","volume":"55","author":"RE Coleman","year":"1987","unstructured":"Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55(1):61\u201366","journal-title":"Br J Cancer"},{"key":"645_CR3","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","volume":"21","author":"BE Hillner","year":"2003","unstructured":"Hillner BE, Ingle JN, Chlebowski RT et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042\u20134057. doi: 10.1200\/JCO.2003.08.017","journal-title":"J Clin Oncol"},{"key":"645_CR4","unstructured":"Warr D, Johnston M (2004) Use of bisphosphonates in women with breast cancer. Practice guideline report no. 1-11. Hamilton ON: Cancer Care Ontario, Program in Evidence-Based Care; 2004. [Available online at: www.cancercare.on.ca\/pdf\/pebc1-11f.pdf ; cited June 15 2008]"},{"issue":"S1","key":"645_CR5","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.3747\/co.2008.176","volume":"15","author":"B Petrut","year":"2008","unstructured":"Petrut B, Trinkaus M, Simmons C et al (2008) A primer of bone metastases management in breast cancer. Curr Oncol 15(S1):S50\u2013S57. doi: 10.3747\/co.2008.176","journal-title":"Curr Oncol"},{"key":"645_CR6","doi-asserted-by":"crossref","unstructured":"Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev CD003474.","DOI":"10.1002\/14651858.CD003474.pub2"},{"issue":"6","key":"645_CR7","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","volume":"16","author":"GN Hortobagyi","year":"1998","unstructured":"Hortobagyi GN, Theriault RL, Lipton A et al (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate, Protocol 19, Aredia Breast Cancer Study Group. J Clin Oncol 16(6):2038\u20132044","journal-title":"J Clin Oncol"},{"key":"645_CR8","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","volume":"17","author":"RL Theriault","year":"1999","unstructured":"Theriault RL, Lipton A, Hortobagyi GN et al (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17:846\u2013854","journal-title":"J Clin Oncol"},{"key":"645_CR9","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0959-8049(99)00331-7","volume":"36","author":"RA Plunkett","year":"2000","unstructured":"Plunkett RA, Smith P, Rubens RD (2000) Risk of complications from bone metastases in breast cancer: implications for management. Eur J Cancer 36:476\u2013482. doi: 10.1016\/S0959-8049(99)00331-7","journal-title":"Eur J Cancer"},{"issue":"3","key":"645_CR10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1634\/theoncologist.11-3-227","volume":"11","author":"MJ Clemons","year":"2006","unstructured":"Clemons MJ, Dranitsaris G, Cole D et al (2006) Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer. Oncologist 11(3):227\u2013233. doi: 10.1634\/theoncologist.11-3-227","journal-title":"Oncologist"},{"issue":"7494","key":"645_CR11","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/bmj.330.7494.769","volume":"330","author":"C Gainford","year":"2005","unstructured":"Gainford C, Dranitsaris G, Clemons M (2005) Recent developments in bisphosphonates for patients with metastatic breast cancer. BMJ 330(7494):769\u2013773. doi: 10.1136\/bmj.330.7494.769","journal-title":"BMJ"},{"key":"645_CR12","doi-asserted-by":"crossref","unstructured":"Gnant M, Mlineritsch B, Schippinger W, et al (2008) Adjuvant ovarian suppression combined with tamoxifen or anastrazole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. Plenary Presentation. ASCO Annual Meeting May 30\u2013June 3","DOI":"10.1200\/jco.2008.26.15_suppl.lba4"},{"key":"645_CR13","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s00520-004-0671-9","volume":"12","author":"S Verma","year":"2004","unstructured":"Verma S, Kerr-Cresswell D, Dranitsaris G et al (2004) Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian medical oncologists. Support Care Cancer 12:852\u2013858. doi: 10.1007\/s00520-004-0671-9","journal-title":"Support Care Cancer"},{"key":"645_CR14","first-page":"e168","volume":"11","author":"M Clemons","year":"2004","unstructured":"Clemons M, Enright K, Cesta A et al (2004) Do physicians follow systemic treatment and funding policy guidelines? Can J Clin Pharmacol 11:e168\u2013e178","journal-title":"Can J Clin Pharmacol"},{"key":"645_CR15","unstructured":"Major P, Cook RJ (2008) Natural History of Skeletal Complications in Patients Receiving Chemotherapy for Breast Cancer Metastatic to Bone. Poster Presentation: SABC December 12\u201314 2008."},{"key":"645_CR16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1634\/theoncologist.2007-0152","volume":"13","author":"A Brufsky","year":"2008","unstructured":"Brufsky A (2008) Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist 13:187\u2013195. doi: 10.1634\/theoncologist.2007-0152","journal-title":"Oncologist"},{"key":"645_CR17","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2106\/00004623-198466040-00016","volume":"66","author":"GE Friedlaender","year":"1984","unstructured":"Friedlaender GE, Tross RB, Doganis AC et al (1984) Effects of chemotherapeutic agents on bone. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rate model. J Bone Joint Surg Am 66:602\u2013607","journal-title":"J Bone Joint Surg Am"},{"issue":"7","key":"645_CR18","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/cncr.21335","volume":"104","author":"Z Chen","year":"2005","unstructured":"Chen Z, Maricic M, Pettinger M et al (2005) Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer. Results from a Subgroup in the Women\u2019s Health Initiative Observational Study. Cancer 104(7):1520\u20131530. doi: 10.1002\/cncr.21335","journal-title":"Cancer"},{"key":"645_CR19","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","volume":"164","author":"ES Siris","year":"2004","unstructured":"Siris ES, Chen Y-T, Abbott TA et al (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108\u20131112. doi: 10.1001\/archinte.164.10.1108","journal-title":"Arch Intern Med"},{"issue":"5","key":"645_CR20","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","volume":"88","author":"A Lipton","year":"2000","unstructured":"Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer 88(5):1082\u20131090. doi: 10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","journal-title":"Cancer"},{"key":"645_CR21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1471-2407-5-89","volume":"5","author":"W Liauw","year":"2005","unstructured":"Liauw W, Segelov E, Anna L et al (2005) Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer. BMC Cancer 5:89. doi: 10.1186\/1471-2407-5-89","journal-title":"BMC Cancer"},{"issue":"suppl 11","key":"645_CR22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0093-7754(01)90228-3","volume":"28","author":"P LoRusso","year":"2001","unstructured":"LoRusso P (2001) Analysis of skeletal related events in breast cancer and response to therapy. Semin Oncol 28(suppl 11):22\u201327. doi: 10.1016\/S0093-7754(01)90228-3","journal-title":"Semin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-009-0645-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-009-0645-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-009-0645-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T22:01:52Z","timestamp":1559080912000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-009-0645-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,8]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["645"],"URL":"https:\/\/doi.org\/10.1007\/s00520-009-0645-z","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,8]]}}}